KAPA
Kairos Pharma, LTD.
Key Financials
Operating Income
$-5572000
↓ 137.8%
EPS (Diluted)
$-0.30
↓ 30.4%
Shareholders' Equity
$6.3M
↑ 32.8%
Cash & Equivalents
$4.5M
↑ 253.1%
Net Income
$-5447000
↓ 109.3%
Total Assets
$6.5M
↑ 13.4%
Total Liabilities
$992000.00
↓ 67.4%
Operating Cash Flow
$-3441000.00
↑ 13.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 424B3 | 4/1/2026 | View on SEC |
| 424B3 | 4/1/2026 | View on SEC |
| 10-K | 3/31/2026 | View on SEC |
| 8-K | 3/2/2026 | View on SEC |
| 8-K | 2/26/2026 | View on SEC |
| EFFECT | 1/23/2026 | View on SEC |
| CORRESP | 1/21/2026 | View on SEC |
| UPLOAD | 1/15/2026 | View on SEC |
| S-3 | 1/13/2026 | View on SEC |
| 4 | 12/30/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KAPA |
| Company Name | Kairos Pharma, LTD. |
| CIK | 1962011 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 818-404-5541 |